Stock AnalizTelix Pharmaceuticals Ltd TLX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Telix Pharmaceuticals Ltd (TLX) is a healthcare company listed in the US with a market value of about $3.1B. In the twelve months to June 30, 2026 it had revenue of $891M and net income of $33M, a net margin of 3.8%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a P/E of 92.3, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $891M | $804M | $517M | $333M |
| Net income | $33M | -$7M | $34M | $4M |
| Free cash flow | -$47M | -$43M | $18M | $8M |
| EPS (diluted) | $0.10 | $-0.02 | $0.10 | $0.01 |
| Net margin | 3.8% | -0.9% | 6.5% | 1.3% |
| ROIC | — | 2.9% | 6.9% | 8.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $19.90, 116% above the current price; targets range from $17.43 to $21.35; the consensus rating is “none”; expected EPS is $0.16 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Telix Pharmaceuticals’s P/E ratio?
About 92.3, based on the last twelve months of diluted earnings per share (forward P/E about 60.3).
Is Telix Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Telix Pharmaceuticals pay a dividend?
Not currently.
Is Telix Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Telix Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.